Joseph Centofanti
Neurology · Cranston, RINPI 1154360543
Payments from drug & device makers
Across 479 payments — averaging $49.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- SK Life Science, Inc.$2K
- AbbVie$2K
- Amgen$746
- Acadia Pharmaceuticals Inc$647
- plus $6K from 32 others
What the payments were for
- Speaking & faculty fees$12,87354%
- Food & beverage$10,79945%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 15 | $7,268 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $4,811 |
| SK Life Science, Inc. | 39 | $2,337 |
| AbbVie(2 entities) | 82 | $1,579 |
| Amgen | 26 | $746 |
| Acadia Pharmaceuticals Inc | 29 | $647 |
| Lilly USA, LLC | 22 | $506 |
| Pfizer | 26 | $493 |
| Amneal Pharmaceuticals LLC | 30 | $452 |
| Teva Pharmaceuticals USA, Inc. | 24 | $445 |
| UCB, Inc. | 16 | $360 |
| Kyowa Kirin, Inc. | 14 | $341 |
| Lundbeck LLC | 9 | $305 |
| Neurelis, Inc. | 12 | $294 |
| Acorda Therapeutics, Inc | 13 | $284 |
| Merz Pharmaceuticals, LLC | 6 | $261 |
| Biogen | 10 | $238 |
| Eisai Inc. | 11 | $236 |
| Adamas Pharmaceuticals, Inc. | 10 | $231 |
| Neurocrine Biosciences, Inc. | 6 | $212 |
| Argenx US, Inc. | 6 | $207 |
| Avanir Pharmaceuticals, Inc. | 10 | $188 |
| MDD US Operations, LLC | 9 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $124 |
| GE HealthCare | 5 | $111 |
| Sanofi | 1 | $100 |
| EMD Serono, Inc. | 1 | $100 |
| Novartis | 5 | $99 |
| Supernus Pharmaceuticals, Inc. | 5 | $98 |
| Tanabe Pharma America, Inc. | 3 | $92 |
| Jazz Pharmaceuticals Inc. | 1 | $81 |
| Avion Pharmaceuticals | 4 | $79 |
| Upsher-smith Laboratories LLC | 3 | $63 |
| Almatica Pharma LLC | 2 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Noctrix Health, Inc. | 1 | $34 |
| Akcea Therapeutics, Inc. | 2 | $33 |
| AstraZeneca | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$11,472
- Cenobamate$1,375
- UBRELVY$224
- INGREZZA$115
- NUPLAZID$114
- XEOMIN$113
- VYEPTI$102
How this compares
$23,756 in reported general payments places this provider in the 75th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $104,804 |
| Nurtec OdtRimegepant Sulfate | 36 | $80,770 |
| NuplazidPimavanserin Tartrate | 13 | $73,250 |
| GocovriAmantadine Hcl | 12 | $40,800 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $38,016 |
| RytaryCarbidopa/Levodopa | 60 | $35,052 |
| QuliptaAtogepant | 21 | $22,386 |
| XadagoSafinamide Mesylate | 13 | $18,524 |
| Emgality PenGalcanezumab-Gnlm | 24 | $16,452 |
| BriviactBrivaracetam | 12 | $16,291 |
| HorizantGabapentin Enacarbil | 12 | $11,694 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 330 | $9,268 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $8,902 |
| Memantine Hcl | 293 | $7,076 |
| Levetiracetam | 137 | $4,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $445 | $104,80414 claims |
| PfizerNurtec Odt | $493 | $80,77036 claims |
| Acadia Pharmaceuticals IncNuplazid | $647 | $73,25013 claims |
| MDD US Operations, LLCGocovri | $163 | $40,80012 claims |
| Amneal Pharmaceuticals LLCRytary | $452 | $35,05260 claims |
| AbbVieQulipta | $1,579 | $22,38621 claims |
| UCB, Inc.Briviact | $360 | $16,29112 claims |
| Upsher-smith Laboratories LLCTopiramate | $63 | $77568 claims |
| Almatica Pharma LLCSertraline Hcl | $59 | $40977 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 86 neurology providers in Rhode Island.
Other neurology in Cranston
- Stephen SallowayProvidence$16.1M
- Brian OttProvidence$4.1M
- Jonathan DrakeProvidence$3M
- Chuang WuProvidence$1.2M
- Peter BellafioreWakefield$274K
- Norman GordonEast Providence$210K
- Syed RizviProvidence$170K
- Albert MaranoJohnston$145K
- Jonathan CahillProvidence$142K
- John EastonProvidence$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.